Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir?

Milaan A. Shaha Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USACorrespondence[email protected]

Katherine G. Beuerleina Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Joseph L. Jorizzob Department of Dermatology, Weill Cornell Medicine, New York, NY, USA;c Wake Forest Baptist Health, Winston Salem, NC, USA

Steven R. Feldmana Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA;d Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA;e Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA;f Department of Dermatology, University of Southern Denmark, Odense, Denmark

https://orcid.org/0000-0002-0090-6289

Click to increase image sizeClick to decrease image size

Disclosure statement

Dr. Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. Milaan Shah, Katherine Beuerlein, and Dr. Joseph Jorizzo have no conflicts to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir?

Information for

Open access

Opportunities

Help and information

Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir?

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature